EGR1 and neoplasm: Only minimal decreases in MVD and increases in the extent of pericyte coverage of residual blood vessels were observed in tumours expressing both EGR1 and HOXB9 after the miR-192 treatments (Fig. 4h), emphasizing the key roles EGR1 and HOXB9 play in mediating the anti-angiogenic effects of miR-192.